Successful Typical AVNRT Ablation
AVNRT is the most common regular arrhythmia in humans, and therefore the most commonly encountered during ablation attempts for regular tachycardias. Case Summary: We present a 41-year-old female patient with chest palpitations in the last 10 years, but prior to hospitalization felt heavy sensation on her chest and hospitalized due to heavy chest palpitations and documented SVT. She had no history of hypertension, diabetes mellitus, coronary heart conditions, or stroke. Physical examination showed fair general condition with GCS E4V5M6, blood pressure 130/80, pulse rate 96x / minute, breath rate 18 x / minute and saturation of 99%. Physical examinations are within normal limits. Discussion: Catheter ablation for AVNRT is the current treatment of choice in symptomatic patients. It reduces arrhythmia-related hospitalizations and costs, and substantially improves quality of life. Catheter ablation approaches aimed at the fast pathway have been abandoned; slow pathway ablation, using a combined anatomical and mapping approach, is now the method of choice. This approach offers a success rate of 95 %, has a recurrence rate of approximately 1.3 – 4.0 %, and has been associated with a low risk of atrioventricular (AV) block.
Gonzalez M, Banchs J, Rivera J. Ablation of Atrioventricular Nodal Reentrant Tachycardia and Variants. Elsevier Inc. 2006;
Chrispin J, Misra S, Marine JE, Rickard J, Barth A, Kolandaivelu A, et al. Current management and clinical outcomes for catheter ablation of atrioventricular nodal re-entrant tachycardia. 2017;1–9.
Heidbu H. How to ablate typical ‘ slow / fast ’ AV nodal reentry tachycardia. 2000;15–9.
Katritsis DG, Data CG. Expert Opinion Catheter Ablation of Atrioventricular Nodal Re-entrant Tachycardia : Facts and Fiction Catheter Ablation of Atrioventricular Nodal Re-entrant Tachycardia. 2018;230–1.
Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomstrom-Lundqvist C, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia The Task Force for the management of patients with supraventricu- lar tachycardia of the European Society of Cardiology ( ESC ). Eur Heart J. 2019;00:1–65.
Knight BP, Verma N. Atrioventricular Nodal Reentrant Tachycardia. Card Electrophysiol. 2020;
Issa Z, Miller J. Clinical Arrhythmology and Electrophysiology A Companion to Braunwald ’ s Heart Disease. 2nd Editio. 2012. 744 p.
Veenhuyzen GD, Mrcp FRQ. Review Article Principles of Entrainment : Diagnostic Utility for Supraventricular Tachycardia. Indian Pacing Electrophysiol J. 2008;8(1):51–65.
Peiker C, Pott C, Eckardt L, Kelm M, Shin D, Willems S, et al. Dual atrioventricular nodal non-re-entrant tachycardia. Europace. 2016;18(June 2014):332–9.
Ho RT, Frisch DR, Pavri BB, Levi SA, Greenspon AJ. Electrophysiological Features Differentiating the Atypical Atrioventricular Node – Dependent. Circ Arrhythm Electrophysiol. 2013;597–606.
Willems S, Weiss C, Shenasa M. Optimized Mapping of Slow Pathway Ablation Guided by Subthreshold Stimulation : A Randomized Prospective Study in Patients With Recurrent Atrioventricular Nodal Re-entrant Tachycardia. J Am Coll Cardiol. 2001;37(6).
Katritsis DG, Zografos T, Katritsis GD, Giazitzoglou E, Vachliotis V, Paxinos G, et al. Catheter ablation vs . antiarrhythmic drug therapy in patients with symptomatic atrioventricular nodal re-entrant tachycardia : a randomized , controlled trial. 2016;1–5.
Stavrakis S, Jackman W, Lockwood D, Nakagawa H, Beckman K, Elkholey, et al. Slow/Fast Atrioventricular Nodal Reentrant Tachycardia Using the Inferolateral Left Atrial Slow Pathway: Role of the Resetting Response to Select the Ablation Target. Circ Arrhythm Electrophysiol. 2018;11(9).
Brachmann J, Lewalter T, Kuck K, Andresen D, Willems S, Spitzer SG, et al. Long-term symptom improvement and patient satisfaction following catheter ablation of supraventricular tachycardia : insights from the German ablation registry. 2017;49:1–10.
Copyright (c) 2022 Angela Bety Ratnasari
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- Cardiovascular and Cardiometabolic Journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License
Authors who publish with Cardiovascular and Cardiometabolic Journal agree to the following terms:
The journal allows the author to hold the copyright of the article without restrictions.
The journal allows the author(s) to retain publishing rights without restrictions.
The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution ShareAlike 4.0 International License (CC BY-SA).